Early-stage biotech programmes routinely lose time, capital and credibility not because the science is weak, but because preclinical planning and regulatory execution are fragmented.

Preqlinic's AI-enabled technology coupled with human expertise makes the preclinical process easier to navigate, more efficient and transparent. This helps biotech firms - and their investors - get treatments to patients faster, reduce waste and spend capital smartly.

PreQlinic provides structured, regulator-informed preclinical blueprints that empower scientists and regulatory teams to plan and execute with greater speed and confidence.

PreQlinic™

Org chart

Teams

Offices